Historical salary details - Mr. Edward T. Mathers, Independent Director, OnKure Therapeutics Inc. - Ordinary Shares - Class A
Mr. Edward T. Mathers is the Independent Director of OnKure Therapeutics Inc. - Ordinary Shares - Class A. They also hold 5 other positions in Trevi Therapeutics Inc, MBX Biosciences Inc., Inozyme Pharma Inc, Synlogic Inc and Rhythm Pharmaceuticals Inc..
Mr. Edward T. Mathers
Independent Director
$ 296.6 K
Gross Remuneration
-
Current Company
OnKure Therapeutics Inc. - Ordinary Shares - Class A
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | OnKure Therapeutics Inc. - Ordinary Shares - Class A | Independent Director | 296.6 K | - |
| 2024 | Trevi Therapeutics Inc | Independent Director | - | - |
| 2024 | MBX Biosciences Inc. | Independent Director | - | - |
| 2024 | Inozyme Pharma Inc | Independent Director | - | - |
| 2024 | Synlogic Inc | Independent Director | - | - |
| 2024 | Rhythm Pharmaceuticals Inc. | Lead Independent Director | - | - |
| 2023 | Rhythm Pharmaceuticals Inc. | Lead Independent Director | 328.8 K | 125.3 % |
| 2023 | Reneo Pharmaceuticals Inc | Independent Director | 165.1 K | 118.1 % |
| 2023 | Senti Biosciences Inc. | Independent Director | 94.7 K | -47.3 % |
| 2023 | Synlogic Inc | Independent Director | 55.7 K | -16.9 % |
| 2022 | Mirum Pharmaceuticals Inc | Independent Director | 329.5 K | 30.6 % |
| 2022 | Senti Biosciences Inc. | Independent Director | 179.9 K | - |
| 2022 | Rhythm Pharmaceuticals Inc. | Lead Independent Director | 145.9 K | -43.1 % |
| 2022 | Reneo Pharmaceuticals Inc | Independent Director | 75.7 K | -60.1 % |
| 2022 | Inozyme Pharma Inc | Independent Director | 73.4 K | -53.9 % |
| 2022 | Synlogic Inc | Independent Director | 67.0 K | -21.0 % |
| 2022 | Trevi Therapeutics Inc | Independent Director | - | - |
| 2022 | Mirum Pharmaceuticals Inc | Independent Director | - | - |
| 2021 | Rhythm Pharmaceuticals Inc. | Lead Independent Director | 256.6 K | -9.0 % |
| 2021 | Mirum Pharmaceuticals Inc | Independent Director | 252.4 K | -2.9 % |
| 2021 | Reneo Pharmaceuticals Inc | Independent Director | 189.9 K | - |
| 2021 | Inozyme Pharma Inc | Independent Director | 159.3 K | 21.6 % |
| 2021 | Synlogic Inc | Independent Director | 84.9 K | 10.2 % |
| 2021 | Trevi Therapeutics Inc | Independent Director | 77.8 K | -5.0 % |
| 2021 | Senti Biosciences Inc. | Independent Director | - | - |
| 2020 | Rhythm Pharmaceuticals Inc. | Lead Independent Director | 281.9 K | 14.7 % |
| 2020 | Mirum Pharmaceuticals Inc | Independent Director | 259.9 K | 1117.3 % |
| 2020 | Inozyme Pharma Inc | Independent Director | 131.0 K | - |
| 2020 | Trevi Therapeutics Inc | Independent Director | 81.8 K | -43.7 % |
| 2020 | Synlogic Inc | Independent Director | 77.0 K | -14.4 % |
| 2020 | Reneo Pharmaceuticals Inc | Independent Director | - | - |
| 2019 | Rhythm Pharmaceuticals Inc. | Independent Director | 245.8 K | 2.3 % |
| 2019 | Trevi Therapeutics Inc | Independent Director | 145.4 K | - |
| 2019 | Synlogic Inc | Independent Director | 90.0 K | -13.1 % |
| 2019 | Mirum Pharmaceuticals Inc | Independent Director | 21.4 K | - |
| 2019 | Liquidia Corp | - | 15.5 K | -93.2 % |
| 2019 | Liquidia Corp | Independent Director | - | - |
| 2019 | Inozyme Pharma Inc | Independent Director | - | - |
| 2018 | Rhythm Pharmaceuticals Inc. | Independent Director | 240.4 K | 2365.6 % |
| 2018 | Liquidia Corp | Independent Director | 228.3 K | - |
| 2018 | Synlogic Inc | Independent Director | 103.5 K | -40.4 % |
| 2018 | Trevi Therapeutics Inc | Independent Director | - | - |
| 2018 | Mirum Pharmaceuticals Inc | Independent Director | - | - |
| 2017 | Synlogic Inc | Independent Director | 173.7 K | - |
| 2017 | Rhythm Pharmaceuticals Inc. | Independent Director | 9.8 K | - |
| 2017 | Liquidia Corp | Independent Director | - | - |
| 2016 | Rhythm Pharmaceuticals Inc. | Independent Director | - | - |
| 2016 | Synlogic Inc | Independent Director | - | - |
| 2015 | Synlogic Inc | Independent Director | 65.1 K | - |
| 2014 | Synlogic Inc | Independent Director | - | - |